查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1383653

代谢性疾病治疗市场 - 全球产业规模、份额、趋势、机会和预测，2018-2028 按疾病类型、治疗类型、地区、竞争预测和机会细分，2018-2028F

Metabolic Disorders Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Disease Type, By Therapy Type, By Region, By Competition Forecast & Opportunities, 2018-2028F
出版日期: | 出版商: TechSci Research | 英文 175 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球代谢紊乱治疗市场价值为 637 亿美元，预计到 2028 年，预测期内将出现令人印象深刻的增长，复合CAGR为7.72%。全球代谢紊乱治疗市场是指致力于开发和治疗疾病的製药和生物技术领域。提供各种代谢紊乱的治疗。代谢紊乱包括影响身体处理和利用营养物质的能力、导致新陈代谢失衡的多种病症。这些疾病可能包括糖尿病、肥胖症、高血脂症和罕见的遗传性疾病，如苯酮尿症和戈谢氏症。

主要市场驱动因素

代谢紊乱的盛行率上升

市场概况
预测期 2024-2028
2022 年市场规模 637亿美元
2028 年市场规模 991.3亿美元
2023-2028 年CAGR 7.72%
成长最快的细分市场 基因治疗
最大的市场 北美洲

糖尿病，尤其是第2型糖尿病，已达到流行程度。世界卫生组织 (WHO) 估计，全球有超过 4.22 亿人患有糖尿病，而且这一数字预计还会上升。作为最普遍的代谢性疾病，糖尿病极大地促进了代谢性疾病治疗市场的扩张。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球代谢紊乱治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型（溶小体贮积症、糖尿病、肥胖、遗传性代谢失调、高胆固醇血症等）
    • 依治疗类型（酵素替代疗法、细胞移植、小分子疗法、底物减少疗法、基因疗法、药物疗法）
    • 按地区
    • 按公司划分 (2022)
  • 产品市场地图
    • 依疾病类型
    • 按治疗类型
    • 按地区

第 6 章：北美代谢紊乱治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型（溶小体贮积症、糖尿病、肥胖、遗传性代谢失调、高胆固醇血症等）
    • 依治疗类型（酵素替代疗法、细胞移植、小分子疗法、底物减少疗法、基因疗法、药物疗法）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲代谢紊乱治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型（溶小体贮积症、糖尿病、肥胖、遗传性代谢失调、高胆固醇血症等）
    • 依治疗类型（酵素替代疗法、细胞移植、小分子疗法、底物减少疗法、基因疗法、药物疗法）
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙

第 8 章：亚太地区代谢失调治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型（溶小体贮积症、糖尿病、肥胖、遗传性代谢失调、高胆固醇血症等）
    • 依治疗类型（酵素替代疗法、细胞移植、小分子疗法、底物减少疗法、基因疗法、药物疗法）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国

第 9 章：南美洲代谢紊乱治疗市场前景

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型（溶小体贮积症、糖尿病、肥胖、遗传性代谢失调、高胆固醇血症等）
    • 依治疗类型（酵素替代疗法、细胞移植、小分子疗法、底物减少疗法、基因疗法、药物疗法）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲代谢紊乱治疗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依疾病类型（溶小体贮积症、糖尿病、肥胖、遗传性代谢失调、高胆固醇血症等）
    • 依治疗类型（酵素替代疗法、细胞移植、小分子疗法、底物减少疗法、基因疗法、药物疗法）
    • 按国家/地区
  • MEA：国家分析
    • 南非代谢紊乱治疗
    • 沙乌地阿拉伯代谢紊乱治疗
    • 阿联酋代谢紊乱治疗
    • 科威特代谢紊乱治疗

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • 商业概览
  • 产品供应
  • 最近的发展
  • 财务（据报导）
  • 主要人员
  • SWOT分析
    • Novo Nordisk A/S
    • Eli Lilly and Co Ltd
    • Shire PLC
    • Sanofi SA
    • Merck KGaA
    • AstraZeneca PLC
    • AbbVie Inc
    • Actelion Pharmaceuticals Ltd
    • Amgen Inc
    • BioMarin Pharmaceutical Inc

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 17532

Global Metabolic Disorders Therapeutics Market has valued at USD 63.70 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.72% through 2028. The Global Metabolic Disorders Therapeutics Market refers to the pharmaceutical and biotechnology sector dedicated to developing and providing treatments for various metabolic disorders. Metabolic disorders encompass a broad range of conditions that affect the body's ability to process and utilize nutrients, leading to imbalances in metabolism. These disorders can include diabetes, obesity, hyperlipidemia, and rare genetic disorders like phenylketonuria and Gaucher's disease.

Key Market Drivers

Rising Prevalence of Metabolic Disorders

Market Overview
Forecast Period2024-2028
Market Size 2022USD 63.70 Billion
Market Size 2028USD 99.13 Billion
CAGR 2023-20287.72%
Fastest Growing SegmentGene Therapy
Largest MarketNorth America

Diabetes, especially type 2 diabetes, has reached epidemic levels. The World Health Organization (WHO) estimates that over 422 million people worldwide have diabetes, and this number is projected to rise. As the most prevalent metabolic disorder, diabetes significantly contributes to the expanding market for metabolic disorder therapeutics.

Obesity, a known risk factor for metabolic disorders, has witnessed a global surge. With sedentary lifestyles, poor dietary habits, and urbanization, obesity rates have skyrocketed. As a result, there is a heightened need for medications and interventions for weight management, diabetes, and related conditions.

The world's aging population plays a pivotal role in the prevalence of metabolic disorders. As individuals age, they are more susceptible to conditions such as type 2 diabetes, metabolic syndrome, and cardiovascular diseases. This demographic shift increases the demand for metabolic disorder therapeutics tailored to the elderly population.

Urbanization is associated with significant lifestyle changes, including reduced physical activity and the consumption of calorie-dense foods. These factors contribute to the development of metabolic disorders, making urban areas hotspots for these conditions. Consequently, urbanization bolsters the market for therapeutics targeting metabolic disorders.

Genetic predisposition to metabolic disorders is a factor that cannot be ignored. Some individuals are genetically prone to conditions like familial hypercholesterolemia or phenylketonuria. The identification of these genetic markers has led to the development of targeted therapies for rare metabolic disorders, driving innovation and growth in the market.

Increased awareness about the risks and consequences of metabolic disorders has prompted more individuals to seek medical attention. Early diagnosis and intervention can help manage these conditions effectively. Patients are now actively involved in managing their health, further boosting the market for therapeutics.

Many governments are recognizing the economic and healthcare burden posed by metabolic disorders. They are implementing preventive measures, public health campaigns, and subsidizing healthcare services for those affected. These initiatives contribute to earlier diagnosis and increased demand for treatment options.

Aging Population

As individuals age, their susceptibility to metabolic disorders, such as type 2 diabetes, cardiovascular diseases, and metabolic syndrome, significantly increases. The natural aging process can lead to changes in metabolism, insulin resistance, and other risk factors, making the elderly a high-priority group for metabolic disorder treatments.

Type 2 diabetes, one of the most prevalent metabolic disorders, is strongly associated with aging. The risk of developing this condition rises with age due to a combination of factors, including hormonal changes and lifestyle habits. Consequently, the aging population contributes to the growing prevalence of diabetes, necessitating a larger market for diabetes therapies.

Aging is a well-established risk factor for cardiovascular diseases, which are often linked to metabolic disorders like hyperlipidemia and hypertension. The elderly are more prone to these conditions, leading to increased demand for therapeutic interventions targeting these disorders.

Aging individuals often require multiple medications for various health conditions. Polypharmacy can lead to drug interactions and complications, emphasizing the need for effective and well-tolerated metabolic disorder therapeutics that can be safely integrated into an elderly patient's medication regimen.

The aging population has prompted healthcare systems to offer more specialized geriatric care. This includes tailoring metabolic disorder treatments to meet the unique needs and challenges faced by older patients. Customized therapeutic approaches are gaining prominence in this context.

Older adults tend to have higher healthcare expenditures due to their greater healthcare needs. As a result, healthcare systems and insurance providers are allocating significant resources to address the specific health issues faced by this demographic, including metabolic disorders.

The desire for an active and healthy lifestyle in later years has become a driving force behind the growth of the metabolic disorders therapeutics market. The elderly population seeks treatments that enable them to maintain their independence and enjoy a high quality of life as they age.

Obesity Epidemic

The obesity epidemic is characterized by a rapid and widespread increase in the prevalence of obesity across the globe. Poor dietary habits, sedentary lifestyles, urbanization, and changing cultural norms have all contributed to this crisis. As obesity rates continue to rise, so does the need for effective therapies to manage related metabolic disorders.

Obesity is a well-established risk factor for various metabolic disorders, including type 2 diabetes, hypertension, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD). Individuals with obesity often exhibit insulin resistance and chronic inflammation, which are central to the development of these disorders.

Type 2 diabetes is one of the most closely associated metabolic disorders with obesity. The increased prevalence of obesity has led to a corresponding surge in type 2 diabetes cases. Consequently, there is a growing demand for diabetes therapeutics, such as insulin and oral hypoglycemic agents, to manage blood sugar levels.

Obesity contributes to elevated levels of triglycerides and LDL cholesterol, increasing the risk of hyperlipidemia and cardiovascular diseases. This connection prompts the need for lipid-lowering drugs and interventions to reduce cardiovascular risk in individuals with obesity.

Obesity-related comorbidities, including sleep apnea, osteoarthritis, and certain cancers, are on the rise. Managing these comorbid conditions often involves medications, surgery, or other therapeutic interventions, contributing to the growth of the metabolic disorders therapeutics market.

In severe cases of obesity, bariatric surgery may be recommended. However, post-operative care often includes ongoing management of metabolic disorders, including monitoring and medication. This underscores the need for comprehensive therapeutic solutions.

The pharmaceutical industry is actively engaged in developing innovative drugs and treatments for obesity and its associated metabolic complications. These treatments aim to address the root causes of obesity, such as hormonal imbalances and appetite regulation.

Advancements in Biopharmaceuticals

Biopharmaceuticals are medications derived from living organisms or their components, such as proteins, DNA, and cells. These drugs have revolutionized the treatment of metabolic disorders by offering targeted therapies with high specificity and efficacy.

Advancements in biopharmaceuticals have paved the way for personalized medicine in the treatment of metabolic disorders. By tailoring treatments to an individual's genetic and metabolic profile, biopharmaceuticals improve the precision and effectiveness of therapies.

Monoclonal antibodies, a prominent class of biopharmaceuticals, have demonstrated remarkable success in the treatment of metabolic disorders. These drugs target specific molecules involved in metabolic pathways, offering a precise way to manage conditions like diabetes and hyperlipidemia.

Biopharmaceuticals have enabled groundbreaking gene therapies for metabolic disorders. These therapies aim to correct genetic mutations responsible for rare metabolic conditions, offering hope for individuals with diseases like phenylketonuria and Gaucher's disease.

Advancements in biopharmaceutical technology have led to the development of insulin analogues that mimic the body's natural insulin response. These analogues offer better blood sugar control for individuals with diabetes and have revolutionized diabetes management.

Rare metabolic disorders, often neglected due to their small patient populations, have benefitted significantly from biopharmaceutical innovation. Orphan drugs, including enzyme replacement therapies, have emerged as life-changing treatments for individuals with rare genetic conditions.

Key Market Challenges

High Development Costs

The research and development of new therapies for metabolic disorders can be prohibitively expensive. The cost of conducting clinical trials, obtaining regulatory approvals, and ensuring safety and efficacy adds significant financial pressure to pharmaceutical and biotech companies.

Regulatory Hurdles

Regulatory approval for metabolic disorder therapeutics can be a lengthy and complex process. Stringent requirements set by regulatory agencies such as the FDA in the United States and the EMA in Europe necessitate extensive testing and documentation, which can delay the market entry of new drugs.

Safety Concerns

The safety of metabolic disorder therapeutics is a paramount concern. Patients with these conditions often require long-term treatment, making it essential to ensure that drugs have minimal side effects and do not compromise patient well-being.

Adherence and Compliance

Managing metabolic disorders often requires ongoing medication and lifestyle modifications. Non-adherence to treatment regimens is a significant challenge, as it can lead to suboptimal outcomes and increased healthcare costs.

Key Market Trends

Precision Medicine and Personalized Therapies

The era of one-size-fits-all treatments is giving way to precision medicine. Genetic profiling, biomarker identification, and patient-specific data are increasingly guiding treatment decisions. Tailored therapies that consider an individual's genetic and metabolic profile promise higher efficacy and reduced side effects in the management of metabolic disorders.

Biopharmaceutical Innovation

Advances in biotechnology are driving the development of innovative biopharmaceuticals for metabolic disorders. Monoclonal antibodies, gene therapies, and RNA-based therapeutics are opening new avenues for treatment, offering more targeted and effective solutions.

Metabolic Syndrome Management

With the rising prevalence of metabolic syndrome-a cluster of conditions including obesity, diabetes, and hypertension-treatment approaches are evolving to address multiple disorders simultaneously. Combinatorial therapies and multifaceted interventions are gaining traction.

Digital Health and Mobile Apps

Mobile applications and digital health platforms are empowering patients to take a more active role in managing their metabolic disorders. These tools offer features like glucose monitoring, dietary tracking, and medication reminders, enhancing disease self-management.

Segmental Insights

Disease Type Insights

Based on the category of Disease Type, Diabetes is poised to dominate the Global Metabolic Disorders Therapeutics Market in 2022 due to several compelling factors. Firstly, the staggering rise in diabetes cases worldwide, driven by lifestyle changes, urbanization, and an aging population, necessitates an increasing demand for effective therapeutic solutions. Secondly, advancements in medical research and technology have led to the development of innovative treatments and therapies for diabetes, enhancing patient outcomes and quality of life. Additionally, governments and healthcare organizations across the globe are increasingly recognizing the economic burden of diabetes and are actively promoting early intervention and treatment, further boosting market growth. Lastly, the global focus on health and wellness, combined with the growing awareness of diabetes-related complications, underscores the urgency for comprehensive metabolic disorder therapeutics. As a result, the diabetes segment is expected to continue dominating the market, offering significant opportunities for pharmaceutical companies and investors alike.

Therapy Type Insights

Drug therapy is poised to dominate the Global Metabolic Disorders Therapeutics Market in 2022 for several compelling reasons. Firstly, pharmaceutical advancements have led to the development of highly effective and targeted medications for various metabolic disorders, offering patients more precise and efficient treatment options. Secondly, the increasing prevalence of metabolic disorders, including obesity, diabetes, and hyperlipidemia, necessitates a robust pharmaceutical presence in the market to address the rising demand for therapeutic solutions. Thirdly, regulatory agencies around the world are encouraging research and development in the pharmaceutical sector to combat metabolic disorders, resulting in a steady stream of innovative drugs entering the market. Additionally, the growing awareness among healthcare professionals and patients about the benefits of drug therapy, such as improved disease management and reduced long-term complications, further strengthens the dominance of drug-based interventions in the global market. Given these factors, drug therapy is poised to maintain its prominent role in shaping the future of the Metabolic Disorders Therapeutics Market.

Regional Insights

North America is set to maintain its dominance in the Global Metabolic Disorders Therapeutics Market in 2022 for several compelling reasons. Firstly, the region boasts a highly developed healthcare infrastructure and a robust pharmaceutical industry, allowing for the rapid development and commercialization of advanced therapies. Secondly, North America has a significant prevalence of metabolic disorders, including obesity and diabetes, primarily driven by dietary and lifestyle factors, contributing to a substantial patient pool seeking treatment. Furthermore, stringent regulatory standards and well-established reimbursement systems ensure that innovative therapies gain swift approval and broad accessibility. Additionally, extensive research and development investments, coupled with a strong emphasis on healthcare innovation, consistently produce cutting-edge treatments, reinforcing North America's market leadership. The region's economic stability and high healthcare spending also make it an attractive market for pharmaceutical companies. Hence, North America is poised to continue dominating the Global Metabolic Disorders Therapeutics Market due to its favorable healthcare ecosystem and commitment to addressing these critical health challenges.

Key Market Players

Novo Nordisk A/S

Eli Lilly and Co Ltd

Shire PLC

Sanofi SA

Merck KGaA

AstraZeneca PLC

AbbVie Inc

Actelion Pharmaceuticals Ltd

Amgen Inc

BioMarin Pharmaceutical Inc

Report Scope:

In this report, the Global Metabolic Disorders Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metabolic Disorders Therapeutics Market, By Disease Type:

  • Lysosomal Storage Diseases
  • Diabetes
  • Obesity
  • Inherited Metabolic Disorders
  • Hypercholesterolemia
  • Others

Metabolic Disorders Therapeutics Market, By Therapy Type:

  • Enzyme Replacement Therapy
  • Cellular Transplantation
  • Small Molecule Based Therapy
  • Substrate Reduction Therapy
  • Gene Therapy
  • Drug Therapy

Metabolic Disorders Therapeutics Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Metabolic Disorders Therapeutics Market.

Available Customizations:

  • Global Metabolic Disorders Therapeutics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Metabolic Disorders Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia, Others)
    • 5.2.2. By Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Product Market Map
    • 5.3.1. By Disease Type
    • 5.3.2. By Therapy Type
    • 5.3.3. By Region

6. North America Metabolic Disorders Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia, Others)
    • 6.2.2. By Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Metabolic Disorders Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Therapy Type
    • 6.3.2. Canada Metabolic Disorders Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Therapy Type
    • 6.3.3. Mexico Metabolic Disorders Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Therapy Type

7. Europe Metabolic Disorders Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia, Others)
    • 7.2.2. By Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Metabolic Disorders Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Therapy Type
    • 7.3.2. United Kingdom Metabolic Disorders Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Therapy Type
    • 7.3.3. France Metabolic Disorders Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Therapy Type
    • 7.3.4. Italy Metabolic Disorders Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Therapy Type
    • 7.3.5. Spain Metabolic Disorders Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Therapy Type

8. Asia-Pacific Metabolic Disorders Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia, Others)
    • 8.2.2. By Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Metabolic Disorders Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Therapy Type
    • 8.3.2. Japan Metabolic Disorders Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Therapy Type
    • 8.3.3. India Metabolic Disorders Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Therapy Type
    • 8.3.4. Australia Metabolic Disorders Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Therapy Type
    • 8.3.5. South Korea Metabolic Disorders Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Therapy Type

9. South America Metabolic Disorders Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia, Others)
    • 9.2.2. By Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Metabolic Disorders Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Therapy Type
    • 9.3.2. Argentina Metabolic Disorders Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Therapy Type
    • 9.3.3. Colombia Metabolic Disorders Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Therapy Type

10. Middle East and Africa Metabolic Disorders Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type (Lysosomal Storage Diseases, Diabetes, Obesity, Inherited Metabolic Disorders, Hypercholesterolemia, Others)
    • 10.2.2. By Therapy Type (Enzyme Replacement Therapy, Cellular Transplantation, Small Molecule Based Therapy, Substrate Reduction Therapy, Gene Therapy, Drug Therapy)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Metabolic Disorders Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Therapy Type
    • 10.3.2. Saudi Arabia Metabolic Disorders Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Therapy Type
    • 10.3.3. UAE Metabolic Disorders Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Therapy Type
    • 10.3.4. Kuwait Metabolic Disorders Therapeutics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Disease Type
        • 10.3.4.2.2. By Therapy Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Novo Nordisk A/S
    • 14.6.2. Eli Lilly and Co Ltd
    • 14.6.3. Shire PLC
    • 14.6.4. Sanofi SA
    • 14.6.5. Merck KGaA
    • 14.6.6. AstraZeneca PLC
    • 14.6.7. AbbVie Inc
    • 14.6.8. Actelion Pharmaceuticals Ltd
    • 14.6.9. Amgen Inc
    • 14.6.10. BioMarin Pharmaceutical Inc

15. Strategic Recommendations

16. About Us & Disclaimer